CRSP
Income statement / Annual
Last year (2025), CRISPR Therapeutics AG's total revenue was $3.51 M,
a decrease of 89.97% from the previous year.
In 2025, CRISPR Therapeutics AG's net income was -$581.60 M.
See CRISPR Therapeutics AG,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$3.51 M |
$35.00 M |
$370.00 M |
$436.00 K |
$913.08 M |
$719.00 K |
$289.59 M |
$3.12 M |
$41.00 M |
$5.16 M |
| Cost of Revenue |
$232.96 M
|
$110.25 M
|
$130.25 M
|
$110.25 M
|
$101.18 M
|
$269.41 M
|
$179.36 M
|
$113.77 M
|
$69.80 M
|
$42.24 M
|
| Gross Profit |
-$229.45 M
|
-$75.25 M
|
$239.75 M
|
-$109.81 M
|
$811.90 M
|
-$268.69 M
|
$110.23 M
|
-$110.65 M
|
-$28.80 M
|
-$37.07 M
|
| Gross Profit Ratio |
-65.37
|
-2.15
|
0.65
|
-251.87
|
0.89
|
-373.7
|
0.38
|
-35.42
|
-0.7
|
-7.18
|
| Research and Development Expenses |
$265.33 M
|
$320.65 M
|
$387.33 M
|
$461.65 M
|
$340.57 M
|
$221.38 M
|
$179.36 M
|
$113.77 M
|
$69.80 M
|
$42.24 M
|
| General & Administrative Expenses |
$73.54 M
|
$72.98 M
|
$76.16 M
|
$102.46 M
|
$99.69 M
|
$85.75 M
|
$63.49 M
|
$48.29 M
|
$35.85 M
|
$31.06 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$73.54 M
|
$72.98 M
|
$76.16 M
|
$102.46 M
|
$99.69 M
|
$85.75 M
|
$63.49 M
|
$48.29 M
|
$35.85 M
|
$31.06 M
|
| Other Expenses |
$0.00
|
-$2.31 M
|
-$1.21 M
|
-$762.00 K
|
-$1.88 M
|
-$221.38 M
|
-$179.36 M
|
-$5.49 M
|
-$197.00 K
|
$78.51 M
|
| Operating Expenses |
$338.87 M
|
$391.32 M
|
$462.29 M
|
$563.35 M
|
$438.38 M
|
$85.75 M
|
$63.49 M
|
$162.07 M
|
$105.65 M
|
$73.29 M
|
| Cost And Expenses |
$571.83 M
|
$501.57 M
|
$592.54 M
|
$673.60 M
|
$539.55 M
|
$355.15 M
|
$242.85 M
|
$162.07 M
|
$105.65 M
|
$73.29 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.05 M
|
| Depreciation & Amortization |
$19.48 M
|
$19.26 M
|
$19.84 M
|
$24.17 M
|
$17.95 M
|
$9.18 M
|
$4.73 M
|
$3.52 M
|
$3.02 M
|
$1.00 M
|
| EBITDA |
-$548.84 M |
-$447.31 M |
-$202.70 M |
-$648.99 M |
$391.48 M |
-$345.25 M |
$51.47 M |
-$155.42 M |
-$61.62 M |
-$13.67 M |
| EBITDA Ratio |
-156.36
|
-12.78
|
-0.55
|
-1488.51
|
0.43
|
-480.18
|
0.18
|
-49.75
|
-1.5
|
-2.65
|
| Operating Income Ratio |
-161.91
|
-13.33
|
-0.6
|
-1543.95
|
0.41
|
-492.96
|
0.16
|
-50.88
|
-1.58
|
-13.19
|
| Total Other Income/Expenses Net |
-$9.65 M
|
$103.90 M
|
$71.82 M
|
$22.66 M
|
$6.00 M
|
$6.38 M
|
$20.57 M
|
-$5.49 M
|
-$1.96 M
|
$45.41 M
|
| Income Before Tax |
-$577.97 M
|
-$362.67 M
|
-$150.72 M
|
-$650.50 M
|
$379.53 M
|
-$348.06 M
|
$67.31 M
|
-$164.43 M
|
-$66.61 M
|
-$22.72 M
|
| Income Before Tax Ratio |
-164.66
|
-10.36
|
-0.41
|
-1491.97
|
0.42
|
-484.08
|
0.23
|
-52.63
|
-1.62
|
-4.4
|
| Income Tax Expense |
$3.63 M
|
$3.59 M
|
$2.89 M
|
-$325.00 K
|
$1.87 M
|
$809.00 K
|
$448.00 K
|
$553.00 K
|
$1.75 M
|
$484.00 K
|
| Net Income |
-$581.60 M
|
-$366.25 M
|
-$153.61 M
|
-$650.18 M
|
$377.66 M
|
-$348.87 M
|
$66.86 M
|
-$164.98 M
|
-$68.36 M
|
-$23.20 M
|
| Net Income Ratio |
-165.7
|
-10.46
|
-0.42
|
-1491.23
|
0.41
|
-485.21
|
0.23
|
-52.81
|
-1.67
|
-4.49
|
| EPS |
-6.47 |
-4.34 |
-1.94 |
-8.36 |
4.97 |
-5.29 |
1.23 |
-3.44 |
-1.71 |
-1.89 |
| EPS Diluted |
-6.47 |
-4.34 |
-1.94 |
-8.36 |
4.7 |
-5.29 |
1.17 |
-3.44 |
-1.71 |
-1.89 |
| Weighted Average Shares Out |
$89.93 M
|
$84.36 M
|
$79.22 M
|
$77.75 M
|
$75.95 M
|
$65.95 M
|
$54.39 M
|
$47.96 M
|
$39.97 M
|
$12.26 M
|
| Weighted Average Shares Out Diluted |
$89.93 M
|
$84.36 M
|
$79.22 M
|
$77.75 M
|
$80.39 M
|
$65.95 M
|
$56.93 M
|
$47.96 M
|
$40.06 M
|
$12.26 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
